Pyramids to myriads: The combination conundrum in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 17, Issue 6 SUPPL. 18, 1999, Pages

  O'Gradaigh, D ^a   Scott, D G I ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Combination; DMARD; Rheumatoid; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; DRUG MONITORING; DRUG RESISTANCE; HUMAN; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS;

EID: 0032695386     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. PINCUS T, CALLAHAN LF, SALES WG et al.: Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
2. BARRETT EM, SYMMONS DPM, SCOTT DGI: Employment attrition in a community based inception cohort of rheumatoid arthritis patients. Br J Rheumatol 1996;35(Suppl. 1): 235.
3. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-22.
4. WILSKE KR, HEALY LA: Remodelling the pyramid - A concept whose time has come (Ed.). J Rheumatol 1989; 16: 565-7.
5. BENSEN WG, BENSEN W, ADACHI JD: Back to the future: The pyramids of rheumatoid arthritis [Ed]. J Rheumatol 1997; 24: 1023-7.
6. FRIES JF: Re-evaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990; 17 (Suppl. 22): 12-15.
7. AREND W: The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40: 595-7.
8. FOX DA: The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997; 40: 598-609.
9. BURMESTER GR, STUHLMULLER B, KEYSZER G, KINNE RW: Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis? Arthritis Rheum 1997; 40: 5-18.
10. FIRESTEIN GS: Invasive fibroblast-like synoviocytes in rheumatoid arthritis; passive responders or transformed aggressors? Arthritis Rheum 1996; 39: 1781-90.
11. MOJCIK CF, SHEVACH EM: Adhesion molecules: A rheumatologic perspective. Arthritis Rheum 1997; 40: 991-1004.
12. TAK PP, SMEETS TMJ, DAHA MR, et al.: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40: 217-25.
13. YANNI G, WHELAN A, FEIGHERY C, BRESNIHAN B: Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 39-44.
14. KEYSER G, REDLICH A, HAUPL T: Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1998; 41: 1378-87.
15. HUMMEL KM, PETROW PK, FRANZ JK, et al.: Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 1998; 25: 1887-94.
16. GRAVALLESSE EM, HARADA Y, WANG J-T, GORN AH, THORNHILL TS, GOLDRING SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943-51.
17. VAN DER HEIJDE DM, VAN RIEL PL, VAN LEEUWEN MA, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LB: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow up study of 147 patients. Br J Rheumatol 1993; 31: 519-25.
18. CUSH JJ, KAVANAUGH AF: Biologic interventions in rheumatoid arthritis. Rheum Dis Clin North Am 1995; 23: 797-816.
19. KAVANAUGH A, COHEN S, CUSH J: Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt? (Ed.) J Rheumatol 1998; 25: 2049-52.
20. DANNING CL, BOUMPAS DT: Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: An update on mechanisms of action. Clin Exp Rheumatol 1998; 16: 595-604.
21. BROOK A, CORBETT M: Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977; 36: 71-3.
22. MCQUEEN FM, STEWART N, CRABBE J et al.: Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57: 350-6.
23. VAN DE HEIDJE DMFM, VAN LEEUWEN MA, VAN RIEL PLCM, et al.: Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Ann Rheum Dis 1992; 35: 26-34.
24. PAULUS HE, VAN DER HEIDJE DMFM, BULPITT KJ, GOLD RH: Monitoring radiographic changes in early rheumatoid arthritis. J Rheumatol 1996; 23: 801-5.
25. WOLFE F, SHARP JT: Radiographic outcome of recent-onset rheumatoid arthritis. Arthritis Rheum 1997; 41: 1571-82.
26. WOLFE F, HAWLEY DJ, CATHEY MA: Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18: 1290-7.
27. EGSMOSE C, LUND B, BORG G, et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
28. GOUGH AKS, LILLEY J, EYRE S, HOLDER RL, EMERY P: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 23-7.
29. GOUGH A, SAMBROOK P, DEVLIN J, et al.: Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: 1282-9.
30. BRENNAN P, HARRISON B, BARRETT E, et al.: A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: A prospective cohort study. Br Med J 1996; 313: 471-6.
31. GOUGH AK, FAINT JM, SALMON M, et al.: Genetic typing of patients with inflammatory arthritis at presentation is predictive of outcome. Arthritis Rheum 1994; 37: 1166-70.
32. WAKEFIELD R, MCGONAGLE D, GREEN MJ, et al.: A comparison of high resolution sonography with MRI and conventional radiography for the detection of erosions in early rheumatoid arthritis. Br J Rheumatol 1998; 37 (Suppl. 1): 105.
33. ARNETT FC, EDWORTHY SM, BLOCK DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
34. EMERY P: Rheumatoid arthritis: Not yet curable with early intensive therapy. Lancet 1997; 350: 304-5.
35. ROUBENOFF R, JONES RJ, KARP JE, STEVENS MB: Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukaemia with cytosine arabinoside, daunorubicin and m-AMSA. Arthritis Rheum 1987; 30: 1187-90.
36. JORGENSEN C, SUN R, ROSSI JF et al.: Expression of a multiple drug resistance gene in human rheumatoid synovium. Rheumatol Int 1995; 15: 83-6.
37. SALMON SE, DALTON WS: Relevance of multiple drug resistance to rheumatoid arthritis: Development of a new therapeutic hypothesis. J Rheumatol 1996; 23 (Suppl. 44): 97-101.
38. WILKE WS, CLOUGH JD: Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 1991: 21 (Suppl. 1): 21-34.
39. FELSON DT, ANDERSON JJ, MEENAN RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 1990; 33: 1449-61.
40. KIRWAN JR and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group: The effects of glucocorticoids and drug destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6.
41. MORRISSON E, CAPELL H: Corticosteroids in the management of rheumatoid arthritis. Br J Rheumatol 1996; 35; 2-4.
42. FURST DE: Cyclosporin, Leflunomide and nitrogen mustard. Baillière's Clin Rheumatol 1995; 9: 711-29.
43. FØRRE Ø and the Norwegian Arthritis Study Group: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporin: Results of a 48-week multicenter study comparing low dose cyclosporin with placebo. Arthritis Rheum 1994; 37: 1506-12.
44. PASERO O, PRIOLO F, MARUBINI E, et al.: Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006-15.
45. SOMERVILLE MF, SCOTT DGI: Neoral - new cyclosporin for old? Br J Rheumatol 1997; 36: 1113-5.
46. FRIES JF, WILLIAMS CA, RAMEY D, BLOCH DA: The relative toxicity of the disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306.
47. WOLFE F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillière's Clin Rheumatol 1995; 9: 619-32.
48. BOERS M, RAMSDEN M: Long-acting drug combinations in rheumatoid arthritis. J Rheumatol 1991: 18; 316-24.
49. FELSON DT, ANDERSON JJ, MEENAN RF: The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994; 37: 1487-91.
50. TUGWELL P: Combination therapy in rheumatoid arthritis: Metaanalysis. J Rheumatol 1996; 23 (Suppl. 44): 43-6.
51. O'DELL JR, HAIRE CE, ERIKSON N, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
52. O'DELL JR, HAIRE C, ERIKSON N, et al.: Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 1996; 23 (Suppl. 44): 72-4.
53. FRIES JF, SINGH G, LENERT L, et al.: Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611-9.
54. HAAGSMA CJ, VAN RIEL PLCM, DE ROOIJ DJRAM et al.: Combination of methotrexate and sulphasalazine vs methotrexate alone: A randomised open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994; 33: 1049-55.
55. HAAGSMA CJ, VAN RIEL PLCM, DE JONG AJL, VAN DE PUTTE LBA: Combination of sulpha-salazine and methotrexate versus the single components in early rheumatoid arthritis: A randomised controlled double-blind 52 week clinical trial. Br J Rheumatol 1997; 36: 1082-8.
56. BOERS M, VERHOEVEN AC, MARKUSSE HM, et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
57. SCHNABEL A, REINHOLD-KELLER E, WILLMANN V: Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994; 14: 33-8.
58. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. New Engl J Med 1995; 333: 137-41.
59. STEIN CM, PINCUS T, YOCUM D, et al.: Methotrexate-Cyclosporin Combination Study Group. Combination therapy of severe rheumatoid arthritis with cyclosporin and methotrexate for forty-eight weeks: An open-label extension study. Arthritis Rheum 1997; 40: 1843-5.
60. BRAWER AE: The combined use of oral methotrexate with intramuscular gold in rheumatoid arthritis. Arthritis Rheum 1988; 31 (Suppl.): R10.
61. WILLIAMS HJ, WARD JR, READING JC et al.: Comparison of auranofin, methotrexate and the combination of both in the treatment of RA. Arthritis Rheum 1992; 35: 259-69.
62. WARD JR, WILLIAMS HJ, EGGER MJ, et al.: Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: A controlled trial. Arthritis Rheum 1983; 26: 1303-15.
63. PINCUS T, MARCUM SB, CALLAHAN LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
64. BENSEN W, TUGWELL P, ROBERTS RM: Combination treatment of cyclosporin with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994; 21: 2034-2038.
65. SCOTT DL, DAWES PT, TUNN E, et al.: Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: A prospective randomised placebo controlled study. Br J Rheumatol 1989: 28; 128-33.
66. SINGLETON PT, CERVANTES AG: Chrysotherapy and concomitant use of antimalarial drug therapy in rheumatoid arthritis. Arthritis Rheum 1982; 25 (Suppl.): S115.
67. LEWIS P, HAZLEMAN B, BULGEN D, et al.: Clinical and immunological study of high dose azothioprine combined with gold therapy. In: GORDON JL and HAZLEMAN BL (Eds.): Rheumatoid Arthritis - Cellular Pathology and Pharmacology. Amsterdam, Elsevier North Holland, 1977; 280.
68. WILKENS RF, UROWITZ MD, STABLEIN DM, et al.: Comparison of azothioprine, methotrexate and the combination of both in the treatment of RA: A controlled trial. Arthritis Rheum 1992; 35: 849-56.
69. WILKENS RF, STABLEIN D: Combination treatment of rheumatoid arthritis using azothioprine and methotrexate: A 48-week controlled clinical trial. J Rheumatol 1996; 23 (Suppl. 44): 64-8.
70. FURST DE: Rational disease-modifying anti-rheumatic drug (DMARD) therapy: Is it possible? (Ed.). Br J Rheumatol 1996; 35: 707-10.
71. CONAGHAN PG, WAKEFIELD RJ, O'CONNOR P, et al.: Intra-articular corticosteroids prevent progression of erosions in metholrexate treated early rheumatoid arthritis. Arthritis Rheum 1998; 41 (Suppl.): s238.
72. STRAND V: The future use of biologic therapies in combination for the treatment of rheumatoid arthritis. J Rheumatol 1996; 23 (Suppl. 44): 91-6.
73. European Mycophenolate Mofetil Cooperative Study Group: Placebo controlled study of mycophenolate mofetil combination with cyclosporin and corticosteroid for prevention of acute rejection. Lancet 1995; 345: 1321-5.
74. KAVANAUGH A, CUSH J, ST CLAIR E, et al.: Anti-TNFα monoclonal antibody treatment of rheumatoid arthritis patients with active disease on methotrexate; results of a double-blind, placebo controlled, multi-center trial [abstract]. Arthritis Rheum 1996; 39 (Suppl.): S123.
75. MAINI R, BREEDVELD F, KALDEN J, et al.: Low dose methotrexate suppresses antiglobulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody (cA2) given repeatedly in rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40 (Suppl.): S126.
76. MORGAN SL, BAGGOTT JE, VAUGUN WH et al.: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo controlled trial. Ann Intern Med 1994; 121: 833-41.